In this study, we identified GGT1 as the ropivacaine-regulated gene in breast cancer cells and subsequently demonstrated that GGT1 depletion abrogated CSC-like phenotypes, both in vitro and in vivo. This evidence concerns the gene GGT1 and breast carcinoma.